Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Eggert K, Skogar O, Amar K, Luotonen L, Kuoppamäki M, Leinonen M, Nissinen H, Oertel W. Eggert K, et al. Among authors: leinonen m. J Neural Transm (Vienna). 2010 Mar;117(3):333-42. doi: 10.1007/s00702-009-0344-4. Epub 2009 Dec 15. J Neural Transm (Vienna). 2010. PMID: 20013007 Clinical Trial.
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Poewe WH, et al. Among authors: leinonen m. Acta Neurol Scand. 2002 Apr;105(4):245-55. doi: 10.1034/j.1600-0404.2002.1o174.x. Acta Neurol Scand. 2002. PMID: 11939936 Clinical Trial.
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S, Poewe W; 006 study group. Olanow CW, et al. Among authors: leinonen m. J Parkinsons Dis. 2021;11(1):177-186. doi: 10.3233/JPD-202285. J Parkinsons Dis. 2021. PMID: 33164945 Free PMC article. Clinical Trial.
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Warren Olanow C, et al. Among authors: leinonen m. Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29. Mov Disord. 2013. PMID: 23630119 Clinical Trial.
491 results